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Abstract
Background: Venous thromboembolism (VTE) and thromboembolic arterial diseases are usually
considered to be distinct entities, but there is evidence to suggest that these disorders may be
linked. The aim of this study was to determine whether a diagnosis of VTE increases the long-term
risk of myocardial infarction (MI).
Methods: The incidence rate (IR) and relative risk (RR) of MI in a cohort of patients with a
diagnosis of VTE (n = 4890) compared with that of a control cohort without prior VTE (n = 43
382) were evaluated in the UK General Practice Research Database (GPRD). Death during follow-
up was also determined. Patients were followed for up to 8 years (mean of 3 years).
Results: The IR of MI per 1000 person-years was 4.1 (95% CI: 3.1–5.3) for the VTE cohort and
3.5 (95% CI: 3.2–3.8) for the control cohort. The IR of MI was highest in the first year after the
VTE episode, but overall differences between the two cohorts were not significant (RR of MI
associated with VTE: 1.2; 95% CI: 0.9–1.6). The risk of death was higher in the VTE cohort than the
control cohort, even after adjustment for cancer, heart failure and ischaemic heart disease (RR: 2.4;
95% CI: 2.2–2.6), particularly during the first year after VTE (RR: 3.8; 95% CI: 3.4–4.3).
Conclusion: A VTE episode does not significantly increase the risk of MI, but does increase the
risk of death, particularly in the first year following VTE diagnosis.
Background
Venous thromboembolism (VTE), usually manifested as
deep vein thrombosis (DVT) or pulmonary embolism
(PE), is usually considered to be a distinct entity from the
thromboembolic arterial diseases, such as myocardial inf-
arction (MI), peripheral artery disease and ischaemic
stroke. However, both VTE and thromboembolic arterial
diseases involve the formation of clots within blood ves-
sels, and so may be linked. Recent studies have investi-
gated the incidence of arterial events in patients with VTE,
and have reported data suggesting that there may be a pos-
itive association between VTE and thromboembolic arte-
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rial disease [1-3]. However, these studies either lacked a
suitable control group or involved relatively small num-
bers of patients.
To determine whether a diagnosis of VTE is associated
with an increased risk of arterial disease, the incidence of
arterial disease in patients with a prior VTE should be
compared with that in matched controls without a history
of VTE. In this study we aimed to perform such an analysis
by assessing the risk of MI in patients with a VTE diagnosis
and control patients without VTE using data recorded pro-
spectively from the UK General Practice Research Data-
base. We also aimed to estimate the overall long-term
mortality among patients with VTE during a long-term
follow-up period in comparison with that of the control
population without VTE.
Methods
Data source
The GPRD contains computerized information entered by
primary care physicians (PCPs) in the UK. The vast major-
ity of the UK population is registered with a PCP. About
1500 PCPs participate in the GPRD, covering a popula-
tion of around 3 million individuals, who are broadly rep-
resentative of the UK population. The PCPs hold the
complete medical record of registered individuals, includ-
ing demographic data, all medical diagnoses, consultant
and hospital referrals, and a record of all prescriptions
issued. Prescriptions are generated directly from the PCP's
computer and entered into the patient's computerized
file. All the information is recorded by PCPs during con-
sultations in a standard fashion and practices regularly
anonymize and send these data to the Medicines and
Healthcare Products Regulatory Agency (MHRA), which is
in charge of quality control and management of the data
for use in research projects. Several validation studies have
shown the accuracy and completeness of data in the
GPRD [4,5]. Previous studies have also confirmed the
validity of using the GPRD for epidemiological research in
the field of DVT and PE [6-10].
Study cohorts
The source population included individuals aged 20–79
years enrolled with a participating PCP for more than 2
years during 1 January 1994 to 31 December 2000, with-
out a previously recorded diagnosis of VTE, as described in
a previous cohort study of the natural history of VTE [11].
The resulting source population consisted of 1 856 206
patients, and the first day of meeting these eligibility crite-
ria was used as each individual's start date. Of this source
population, 6550 patients had a first recorded diagnosis
of VTE from the individual's start date until 31 December
2000. The validation (positive predictive value) of a VTE
diagnosis in the GPRD has been described previously: a
questionnaire was sent to PCPs for a random sample of
5% of patients with a record of VTE and, after reviewing
these questionnaires, the diagnosis of VTE was confirmed
in 94% of cases [11]. Moreover, we previously reported
that the overall incidence rate of VTE in the study cohort
was 74.5 per 100 000 person-years [11]. In other epidemi-
ological studies, the incidence of VTE ranged from 71 to
117 case per 100 000 of the population per year (stand-
ardized for age and sex) [12].
We classified VTE episodes as idiopathic if they occurred
in the absence of the following transient risk factors: frac-
ture, surgery, pregnancy or childbirth, or any hospitaliza-
tion (all occurring in the 3-month period before VTE);
cancer in the year before VTE; or use of hormone replace-
ment therapy or oral contraceptives in the 6 months
before the date of the VTE episode. We considered all
other cases of VTE to be secondary, in a similar manner to
other studies [1,13].
A control cohort was also identified. For this, 50 000 indi-
viduals without a VTE diagnosis were randomly sampled
from the source population and matched by age, sex and
calendar year to the VTE cohort.
Definition of clinical endpoints
Myocardial infarction
Patients with a history of ischaemic heart disease prior to
their start date were excluded from both VTE and control
cohorts for the analysis of the risk of MI following a VTE,
as a history of ischaemic heart disease could mask the
influence of VTE on a subsequent MI. Each individual's
start date was the date of diagnosis of VTE in the VTE
cohort and a random date within the study period for the
control cohort. Follow up started a month after the start
date in order to exclude patients dying due to the initial
episode of VTE. Finally, there were 4890 patients in the
VTE cohort and 43 382 patients in the control cohort.
Patients in both cohorts were then followed up until one
of the following endpoints was reached: a recorded code
of MI, age of 80 years, death or the end of the study period
(31 December 2002). We manually reviewed the compu-
terized profiles of all patients identified with a code of MI,
and all deaths. We considered MI cases to be patients
whose diagnosis was confirmed by a letter from a consult-
ant cardiologist or on hospital discharge. We also consid-
ered as cases: those who died from coronary heart disease
(CHD); patients with post-mortem evidence of a recent
MI or a recent coronary artery occlusion; patients with
ante-mortem evidence of CHD in the absence of another
cause of death; and patients for whom CHD was recorded
as the underlying cause of death. We did not contact PCPs
for further confirmation of the diagnosis of MI, as our
experience from a previous study of MI in the GPRD has
shown that case ascertainment after manual review of theThrombosis Journal 2008, 6:10 http://www.thrombosisjournal.com/content/6/1/10
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computerized information supports our case definition in
more than 90% of instances [14].
Mortality
For the mortality analysis, individuals with a history of
ischaemic heart disease prior to the start date were not
excluded, but follow-up was started 1 month after the epi-
sode of VTE as before. (Data for patients who died within
the first month of the VTE diagnosis have been presented
elsewhere [11].) The VTE cohort consisted of 5801
patients and the control cohort consisted of 48 399
patients. Patients were followed until death, age of 80
years or the end of the study period (31 December 2002).
Analysis of MI risk
Relative risk and Kaplan-Meier survival analysis
Estimates of MI occurrence (with 95% CI) were calculated
for the VTE and control cohorts. Individuals alive at the
end of the study period were regarded as censored from
that date, while individuals with their last practice visit
before the end of the study were regarded as censored
from the date of their last practice visit. The cumulative
hazard of MI was calculated using a Kaplan-Meier survival
analysis. Cox proportional hazards regression was used to
estimate the relative risk (RR) and 95% confidence inter-
vals of MI in the VTE cohort compared with the control
cohort (overall and according to type of VTE). Variables
included in the multivariate model were the presence of
heart failure and hypertension, as well as frequency-
matched variables (age, sex, and calendar year).
Analysis of mortality
Deaths from any cause during the follow-up period were
analysed using Kaplan-Meier life-tables to compare sur-
vival between patients with or without VTE. Cox propor-
tional hazards regression was used to estimate the RR and
95% CI of death in the VTE cohort compared with the
comparison cohort. Variables included in the multivariate
model were the presence of cancer or heart failure as well
as the frequency-matched variables (age, sex and calendar
year). All statistical analyses were conducted using STATA
(version 8.2; Stata Corporation, College Station, Texas,
USA).
Results
Risk of myocardial infarction
The incidence and risk of MI were determined for the
cohort of VTE patients (n = 4890) and the control cohort
(n = 43 382), in order to provide an estimate of the RR of
MI following VTE. The age distribution in the two cohorts
was successfully matched, with 12.3% of both cohorts
aged 20–39 years, 33.3% aged 40–59 years, 27.1% aged
60–69 years and 27.3% aged 70 years or older. During the
mean follow-up period of 3 years (range: 3–8 years;
median: 3 years), MI occurred in 55 patients from the VTE
cohort and 472 patients from the control cohort. Thus the
incidence rate (IR) of MI per 1000 person-years was 4.1
(95% CI: 3.1–5.3) for the VTE cohort and 3.5 (95% CI:
3.2–3.8) for the control cohort. The difference between
the two groups was not significant, as shown by the RR of
MI (RR: 1.2; 95% CI: 0.9–1.6). The incidence rates of MI
were within the range reported in previous population-
based studies in the UK (2.73–8.23 and 0.66–2.56 per
1000 person-years in men and women, respectively
[15,16]).
The IR of MI increased with age in both cohorts (see Figure
1). Although the IR of MI was numerically greater in the
VTE cohort than the control cohort for those aged 60–69
years or at least 70 years, determination of RR indicated
that these differences were not significant (RR: 1.3; 95%
CI: 0.8–2.0 for patients aged 60–69 years, RR: 1.4; 95%
CI: 0.9–2.0 for those aged 70 years or more). The cumula-
tive proportion of patients diagnosed with MI over time
for the two cohorts is shown in Figure 2. This analysis
showed that the cumulative proportion of patients with
MI was slightly greater in the VTE cohort than the control
cohort in the first year, but this difference narrowed in
years 2–4. Indeed, the increased risk of MI in the VTE
cohort compared with the control cohort in the first year
was of borderline significance (adjusted RR: 1.6; 95% CI:
1.0–2.5). After the first year, the adjusted RR of MI associ-
ated with VTE fell to 1.0 (95% CI: 0.7–1.5).
Incidence rate (IR) and relative risk (RR) of myocardial infarc- tion in the venous thromboembolism (VTE) cohort and con- trol cohort according to age Figure 1
Incidence rate (IR) and relative risk (RR) of myocar-
dial infarction in the venous thromboembolism 
(VTE) cohort and control cohort according to age.Thrombosis Journal 2008, 6:10 http://www.thrombosisjournal.com/content/6/1/10
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Further analysis of the risk of MI in the VTE cohort com-
pared with the control cohort for the first year showed
that the excess risk was of borderline significance in
patients aged between 60 and 69 years (RR: 2.0; 95% CI:
1.0–4.0) and insignificant in the younger age group (40–
59 years of age, RR: 0.70; 95% CI: 0.1–5.3) and older age
group (≥70 years, RR: 1.5; 95% CI: 0.8–2.9). The risk of
MI in the VTE cohort, however, was similar for patients
who had had DVT (n = 33) and for patients who had had
PE with or without DVT (n = 22) (Table 1). The risk of MI
was also similar regardless of whether the VTE was idio-
pathic or secondary (Table 1).
Mortality
During the total follow-up period of 8 years, 3088
patients died: 2266 of 48 399 in the control cohort and
822 of 5801 in the VTE cohort. Overall mortality was,
therefore, higher in the VTE cohort (14.2%; 49.5 per 1000
person-years) than the control cohort (4.7%; 14.5 per
1000 person-years) (Figure 3). After adjustment for the
presence of cancer, ischaemic heart disease and heart fail-
ure, the RR of death during this 8-year period in the VTE
cohort compared with the control cohort was 2.4 (95%
CI: 2.2–2.6). When we re-analyzed the mortality findings
after excluding patients with a history of ischaemic heart
disease to allow comparison with the incidence of MI in
these cohorts, the mortality rates dropped to 47.4 and
Cumulative proportion of patients diagnosed with myocardial infarction (MI) in the venous thromboembolism (VTE) cohort  and control cohort over time (log-rank test > 0.05) Figure 2
Cumulative proportion of patients diagnosed with myocardial infarction (MI) in the venous thromboembolism 
(VTE) cohort and control cohort over time (log-rank test > 0.05).
Table 1: Incidence rate and relative risk of myocardial infarction in the venous thromboembolism cohort compared with the control 
cohort in the first year of follow up.
Myocardial
infarction
  cases (n = 159)
Incidence
rate per 1000
  person-years
Relative risk
 (95% CI)a
Control cohort (n = 43 382) 136 3.4 (2.9–4.0) 1
Venous thromboembolism cohort (n = 4890) 23
Deep vein thrombosis 15 5.7 (3.4–9.4) 1.7 (1.0–2.9)
Pulmonary embolism 8 4.8 (2.4–9.6) 1.5 (0.7–3.1)
Secondary venous thromboembolism 13 5.2 (3.0–8.9) 1.6 (1.0–2.8)
Idiopathic venous thromboembolism 10 5.6 (3.0–10.4) 1.6 (0.8–3.2)
aAdjusted relative risk derived from Cox regression models including sex, age, calendar year, heart failure, hypertension, and smoking.Thrombosis Journal 2008, 6:10 http://www.thrombosisjournal.com/content/6/1/10
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12.1 per 1000 person-years in the VTE and control
cohorts, respectively.
The increased risk of death associated with VTE was much
greater in the first year after VTE diagnosis (RR: 3.8; 95%
CI: 3.4–4.3) than in subsequent years (RR: 1.6; 95% CI:
1.8–1.4) (Table 2). The risk of death in the first year was
also greater in patients with a diagnosis of DVT (RR: 4.4;
95% CI: 3.9–5.1) than in those with a diagnosis of PE (RR:
2.9; 95% CI: 2.5–3.5) (Table 2). Compared with the con-
trol group, mortality was increased in patients aged 20–59
years (RR: 10.5; 95% CI: 7.3–15.1) and at least 60 years
(RR: 3.1; 95% CI: 2.7–3.6).
Causes of death for patients dying within the first year of
follow up are shown in Table 3. The main cause of death
was cancer in both groups, but the percentage of patients
dying from cancer was almost two-fold higher in the VTE
group (56.0 vs. 29.6%). Conversely, the proportion of
patients dying from CHD was approximately two-fold
greater in the control cohort than the VTE cohort.
Kaplan-Meier survival curves for venous thromboembolism (VTE) cohort and control cohort (*log-rank = 1005.25; p < 0.005) Figure 3
Kaplan-Meier survival curves for venous thromboembolism (VTE) cohort and control cohort (*log-rank = 
1005.25; p < 0.005).
Table 2: Mortality and relative risk of MI in the venous thromboembolism cohort compared with the control cohort, according to year 
of follow up.
First year After 1 year
Deaths
 (n = 1216)
Mortality/1000
person-years
  (95% CI)
RR (95%
 CI)a
Deaths
 (n = 1872)
Mortality/1000
person-years
  (95% CI)
RR (95% CI)a
Control cohort 716 16.0 (14.9–17.1) 1 1550 13.9 (13.2–14.6) 1
All VTE cases 500 97.8 (89.6–106.8) 3.8 (3.4–4.3) 322 28.1 (25.2–31.3) 1.6 (1.4–1.8)
DVT 344 113.4 (102.0–126.1) 4.4 (3.9–5.1) 186 27.7 (24.0–32.0) 1.6 (1.4–1.9)
PE 156 75.1 (64.2–87.9) 2.9 (2.5–3.5) 136 28.7 (24.2–33.9) 1.6 (1.3–1.9)
CI, confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; RR, relative risk; VTE, venous thromboembolism.
aRelative risk estimated by Cox regression adjusted for age, sex, calendar year, consultations in the previous year, cancer, heart failure and 
ischaemic heart disease.Thrombosis Journal 2008, 6:10 http://www.thrombosisjournal.com/content/6/1/10
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Discussion
The results of this study suggest that a first VTE episode
does not increase the risk of MI. These results were similar,
regardless of VTE type (DVT or PE), or whether VTE was
idiopathic or secondary. However, while we did not
observe a significant increase in the risk of MI following
VTE (RR: 1.2 with a lower 95% CI below 1.0), the upper
95% confidence interval of 1.6 means that an increased
risk of MI following VTE cannot be safely excluded on the
basis of our results.
These results contrast with several, much smaller, studies
that have pointed towards an association between VTE
and thromboembolic arterial disease. Case-control stud-
ies have reported a significantly higher prevalence of
carotid plaques in patients with DVT (n = 299) [17] and a
significantly higher incidence of coronary artery calcifica-
tion in patients with idiopathic VTE (n = 89) compared
with matched controls lacking VTE [18]. Moreover, Bova
and colleagues found a significantly higher risk of arterial
events in 151 patients with VTE compared with 151 con-
trols (HR 2.9; 95% CI: 1.1–7.6) [13]. Recently, a cohort
study reported the risk of MI to be increased by 60% in the
first year after an episode of VTE, with a progressive
decline during the subsequent 20 years [19]. As the
present study includes nearly 5000 patients with VTE and
a control cohort without prior VTE (n = 43 382), our con-
clusion that VTE is not associated with a major increased
risk of subsequent MI is likely to be authoritative.
The conclusions of our study contradict those of Bova and
colleagues [13], but this may reflect, in part, differences in
the criteria used to identify patients with VTE and the arte-
rial events used as endpoints. Moreover the latter study
was comparatively small, though to our knowledge it is
the only study other than ours and the aforementioned
study by Hong et al. in 89 patients with VTE [18] to com-
pare patients with VTE with controls taken from a general
population without VTE. Other studies investigating VTE
as a risk factor for cardiovascular events did not include a
control group without VTE. For example, two studies
compared patients with idiopathic VTE with patients diag-
nosed with secondary VTE [1,2], and one investigated the
long-term effects of 6 weeks vs 6 months of anticoagula-
tion treatment on patients with VTE [3]. Given the large
number of patients with first VTE (n = 4890) in our study,
it seems unlikely that VTE is associated with a subsequent
MI for patients without a history of ischaemic heart dis-
ease.
In contrast to the conflicting results surrounding the asso-
ciation between DVT and cardiovascular disease, it is well
recognised that there is an increased mortality after VTE
[3]. The present study showed that a first diagnosis of VTE
was associated with significantly increased mortality in
those who survived the first month following the VTE
event, particularly in the subsequent 11 months after VTE
diagnosis. This risk was greatest in patients with DVT
rather than PE, and in younger patients rather than the
elderly. Previous studies have shown that mortality is
highest immediately after VTE in patients with PE, and
then decreases over the following year [20,21]. However,
to our knowledge, few studies have investigated mortality
in patients for prolonged periods after VTE. Our study
therefore provides important data on long-term mortality
following a VTE event in a large number of patients (n =
5801). These findings complement those from a previous
study in the same cohort of patients with VTE which
reported patient mortality in the first month after VTE
[11].
The present study showed that, during the first year after
VTE, cancer was the most frequent cause of death in VTE
patients surviving the first month. Cancer is a well-known
risk factor for VTE and death from VTE [3,11,22-24], with
the mortality seemingly independent of whether the can-
cer diagnosis is made before or after VTE diagnosis [24].
As such, cancer (and death because of cancer) is likely to
be more common in the VTE cohort. Secondly, the data
for this period may be skewed somewhat, as the 1-month
period after VTE is omitted. During this 1-month period
there were more deaths due to cardiovascular causes than
cancer, as has been reported previously [11]. Deaths dur-
ing the 1-month period after VTE were largely due to PE,
rather than DVT, with the 1-month death rate of 1.4%
Table 3: Distribution of causes of death in patients dying during the 11 months of follow up in patients with VTE surviving the first 
month after VTE diagnosis in comparison with control cohort.
Cause of death VTE cohort (n = 500)
 n (%)
Control cohort (n = 716)
 n (%)
Coronary heart disease (CHD) 49 (9.8) 153 (21.4)
Other cardiovascular and cerebrovascular diseases 63 (12.6) 107 (14.9)
Cancer 280 (56.0) 212 (29.6)
Other non-cardiovascular diseases (respiratory, digestive, urinary, other) 47 (9.4) 129 (18.0)
Unknown 61 (12.2) 115 (16.1)Thrombosis Journal 2008, 6:10 http://www.thrombosisjournal.com/content/6/1/10
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after an episode of DVT and 22.6% after PE with or with-
out DVT [11].
The 8-year risk of death in patients surviving the first
month after VTE is higher than that in patients without
VTE, even after adjustment for cancer, heart failure and
ischaemic heart disease. Because of the likely multiple
comorbid diseases and risk factors in the predominantly
elderly population with VTE in this study, we should be
cautious about the reasons for this excess mortality. Thus,
although the 8-year risk of death in patients surviving 1-
month after VTE is higher than that in patients without
VTE, it is difficult to say whether this increased risk arises
from VTE itself or other underlying conditions or risk fac-
tors.
This study has a number of important strengths. Patients
were drawn from a large primary care database represent-
ative of the UK population and spanning a wide age range,
and representing a study population that is an order of
magnitude larger than previous studies investigating
potential risk factors and complications of VTE
[13,17,18,25-29]. Cases of VTE were classified according
to whether they were DVT or PE, and also if they were idi-
opathic or secondary, allowing analysis of possible differ-
ences between the types of VTE. VTE cases in a random
sample were also identified and validated with a confir-
mation rate of over 94% [11]. We excluded information
bias since information was collected in the same manner
for VTE and comparison patients, and information collec-
tion in VTE cases was blinded to the later occurrence of
MI. Using MI, a major clinical event, as the cardiovascular
endpoint was advantageous as previous studies using the
GPRD have shown the validity of using codes for MI
[14,30]. Limitations of the study include the fact that it
only involved a UK population sample and that patients
included in the analysis of MI risk may have had subclin-
ical cardiovascular disease prior to the start date of the
study. Patients may also have had VTE or MI prior to
enrolment in the GPRD, which would not have been sys-
tematically recorded. In addition, the limited number of
MI cases in the VTE cohort (55) means that the study is
not powered to detect modest but potentially clinically
important elevations in the incidence rate of MI.
Conclusion
In conclusion, our data show that a diagnosis of VTE does
not increase the risk of MI in comparison with a control
cohort drawn from the general population of the UK.
There was some suggestion that the risk of MI may be
increased in elderly patients with VTE during the first year
following the diagnosis of VTE, but this increase was not
statistically significant. While the risk of MI is not
increased, patients who survive the first month after a VTE
event were significantly more likely than controls to die in
the subsequent 8 years. This increased risk is particularly
marked over the first year following a VTE. Further studies
may thus be required to investigate the causes of death fol-
lowing VTE in more detail, and thus determine how best
to reduce mortality in patients after a first VTE event.
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